Extended Data Fig. 2: Subgroup analyses for the secondary end points. | Nature Medicine

Extended Data Fig. 2: Subgroup analyses for the secondary end points.

From: Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial

Extended Data Fig. 2

Forest plots show results of prespecified subgroup analyses for the secondary efficacy end points: conditioning regimen MAC or RIC; with or without ATG; CNI tacrolimus or cyclosporine; HLA match; and stem cell source peripheral blood or bone marrow. Analyses included all randomized patients who received ≥1 dose of study treatment and allo-HSCT; statistical tests were two-sided. Hazard ratios plotted with 95% confidence intervals were obtained via Cox proportional hazard model with treatment group stratified by randomization strata. Allo-HSCT, allogeneic hematopoietic stem cell transplantation; ATG, anti-thymocyte globulin; aGVHD, acute graft-versus-host disease; CNI, calcineurin inhibitor; HLA, human leukocyte antigen; MAC, myeloablative conditioning; RIC, reduced intensity conditioning.

Back to article page